Regulatory Approval Delays or Failure: Virax Biolabs operates in highly regulated environments, and the failure to obtain or maintain necessary regulatory approvals (e.g., CE marking, NMPA, FDA) for its diagnostic tests and other products could severely hinder its ability to market and sell products, leading to significant delays and lost revenue opportunities.

Intense Market Competition: The diagnostic and life sciences markets are highly competitive and characterized by rapid technological change. Virax faces competition from larger, well-established companies with greater resources, which could lead to pricing pressures, reduced market share, and challenges in gaining customer adoption for its products.

Dependence on Third-Party Manufacturers: Virax often relies on third-party manufacturers and suppliers for the production of its products and components. Any disruption in this supply chain, quality control issues from these partners, or an inability to secure favorable manufacturing agreements could lead to product shortages, increased costs, and reputational damage.